+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Telmisartan"

From
Telmisartan Market Report and Forecast 2024-2032 - Product Thumbnail Image

Telmisartan Market Report and Forecast 2024-2032

  • Report
  • October 2024
  • 200 Pages
  • Global
From
Angiotensin Receptor Blockers (ARBs) Market Report 2025 - Product Thumbnail Image

Angiotensin Receptor Blockers (ARBs) Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
ACE/ARB Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

ACE/ARB Inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Hypertension Drugs Markets in China - Product Thumbnail Image

Hypertension Drugs Markets in China

  • Report
  • November 2023
  • 215 Pages
  • China
From
Hypertension Drugs Industry Forecasts - China Focus - Product Thumbnail Image

Hypertension Drugs Industry Forecasts - China Focus

  • Report
  • November 2023
  • 109 Pages
  • China
From
  • 11 Results (Page 1 of 1)
Loading Indicator

Telmisartan is a drug used to treat high blood pressure and reduce the risk of cardiovascular disease. It belongs to a class of drugs known as angiotensin receptor blockers (ARBs). Telmisartan works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow, leading to an increase in blood pressure. It also helps to reduce the risk of stroke, heart attack, and other cardiovascular events. Telmisartan is usually taken once a day, with or without food. It is available in tablet form and is usually taken with other medications to treat high blood pressure. Telmisartan is a widely used drug in the cardiovascular market. It is used to treat hypertension, reduce the risk of stroke and heart attack, and improve overall cardiovascular health. It is also used to reduce the risk of developing type 2 diabetes. Companies in the Telmisartan market include Pfizer, Novartis, Merck, Sanofi, and AstraZeneca. Show Less Read more